- Home
- YSG vs FBRX Comparison
YSG vs FBRX Comparison
Compare YSG & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSG | FBRX |
|---|---|---|
| Founded | 2016 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.3M | 379.3M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | YSG | FBRX |
|---|---|---|
| Price | $3.93 | $29.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 93.1K | ★ 180.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $28.96 | N/A |
| Revenue Next Year | $16.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.30 | $4.91 |
| 52 Week High | $11.04 | $35.62 |
Technical Indicators
Market Signals| Indicator | YSG | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 50.40 |
| Support Level | $3.89 | $26.67 |
| Resistance Level | $4.43 | $32.12 |
| Average True Range (ATR) | 0.22 | 2.38 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 20.69 | 48.53 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).